RC Medical is challenging the conventional path of medical device development by reversing the usual order of operations. Rather than starting with an engineer's concept and searching for a clinical application, the Lake Forest, California-based venture studio begins in the interventional suite, where physicians encounter unmet needs weekly. "We go to the interventional suite first," said David Ferrera, CEO of RC Medical. "The physicians there see the gaps every week. Our job is to listen, then build the company around what they're actually describing." This approach positions the studio as a partner to physician-entrepreneurs rather than a contract developer, with the goal of identifying new technology and new indications for devices before forming a standalone company around each idea.
The significance of this model lies in its potential to capture clinical insights that traditional product roadmaps often miss. Ferrera, who has spent nearly three decades building devices for interventional neuroradiology and related fields, including as co-founder of Blockade Medical and Chief Technology Officer of Balt Global, argues that the details physicians observe in daily practice rarely surface in conventional development. "A catheter that works in a textbook case can still fail in the specific anatomy a physician sees three times a week," he said. "That detail doesn't show up unless you're building with the physician, not for them." By embedding that feedback from the first sketch through commercialization, the studio model aims to catch design flaws early, before a device design is locked in and difficult to change.
RC Medical's structure also differs from a typical portfolio company. When an idea clears the early bar, the studio does not fold it into an existing product line; instead, it forms a new company with its own team and focus. "Each idea gets its own company, its own team, its own focus," Ferrera said. "A big portfolio company can lose a good idea in the shuffle. A newco can't afford to." That strategy has produced three separate companies so far: Single Pass, Infinity Neuro, and Sonorous NV. Each grew out of a specific problem described by a physician in the interventional suite and now operates as an independent business rather than a product line inside RC Medical.
For interventional radiology, where procedural complexity and device performance are tightly linked to patient outcomes, the implications are notable. The studio model could shorten the distance between clinical observation and commercial product, while giving physician-entrepreneurs a structured path to turn insight into a viable company. Ferrera is candid that the model is not for every idea. "Some ideas are better as a feature of an existing product, not a new company," he said. "Part of the first conversation is being honest about which one this is." For ideas that do become a newco, physician involvement often continues through development and toward market launch, keeping the clinical need in view at every stage rather than only at the start. Ferrera is also the author of "Innovation in Translation: How Big Ideas Really Happen," published by Forbes Books in 2021.
